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Abstract
Background: Interoperability standards intend to standardise health information, clinical practice guidelines intend
to standardise care procedures, and patient data registries are vital for monitoring quality of care and for clinical
research. This study combines all three: it uses interoperability specifications to model guideline knowledge and
applies the result to registry data.
Methods: We applied the openEHR Guideline Definition Language (GDL) to data from 18,400 European patients in
the Safe Implementation of Treatments in Stroke (SITS) registry to retrospectively check their compliance with
European recommendations for acute stroke treatment.
Results: Comparing compliance rates obtained with GDL to those obtained by conventional statistical data analysis
yielded a complete match, suggesting that GDL technology is reliable for guideline compliance checking.
Conclusions: The successful application of a standard guideline formalism to a large patient registry dataset is an
important step toward widespread implementation of computer-interpretable guidelines in clinical practice and
registry-based research. Application of the methodology gave important results on the evolution of stroke care in
Europe, important both for quality of care monitoring and clinical research.
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Background
Several standardisation efforts are being made to tackle
the issue of widely non-interoperable health information
systems. Reaching interoperability would mean that dif-
ferent health information systems could exchange infor-
mation between each other and the receiving system
would additionally understand what has been sent to it,
and not only be able to read it. Examples of those efforts
are the standardisation specifications developed by Health
Level Seven International (HL7) [1], the International
Organization for Standardization (ISO) [2], the openEHR
Foundation [3], the Clinical Information Modeling Initiative
(CIMI) [4], the International Health Terminology Standards
Development Organisation (IHTSDO) [5] and the World
Health Organization (WHO) [6].
The means by which these efforts aim to reach inter-
operability differ in the sense that the proposed solutions
address different aspects of interoperability. While some
of them, e.g. HL7 FHIR, the ISO standard 13606 and
openEHR, offer standardised information models which
include data types and classes that are tailored to health
care, others focus more on providing standardised terms,
e.g. IHTSDO and WHO through their terminologies
SNOMED CT and ICD respectively. The different ap-
proaches are, however, interconnected as data elements
from the former kind can often be bound to standardised
terms from the latter type of initiatives.
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Clinical practice guidelines (from now on referred to
as ‘guidelines’) are ‘systematically developed statements
to assist practitioner and patient decisions about appro-
priate health care for specific circumstances’ based on
the latest evidence in the respective clinical field, e.g.
diagnostic or treatment-related decisions [7]. Complying
with guideline recommendations is expected to increase
the numbers of patients treated according to best evi-
dence and improve outcomes.
While guidelines are products of research, registries
are tools that store patient data tailored for conducting
research on a particular disease or treatment modality.
Registries obtain their data in different ways, e.g. directly
from electronic health records or through manual data
entry by designated health care professionals.
Here we report on the use of a formalism for modelling
guideline knowledge based on openEHR specifications, the
Guideline Definition Language (GDL), to represent stroke
guidelines and run the resulting computer-interpretable
guidelines on data from the Safe Implementation of
Treatments in Stroke (SITS) registry. GDL is a rule-based
language that has recently been added to the openEHR
specifications [8]. The SITS registry is a prospective,
multinational, observational registry for medical centres
documenting stroke treatments since 2002 [9].
We have previously experimentally tested a method-
ology in which we modelled guideline knowledge using
GDL, in order to check the compliance of 49 mock
stroke patient cases with European Stroke Organisation
guidelines, with promising results [10]. The implications
of the success of such a methodology are obtaining
shareable evidence-based knowledge models that can be
used not only for guideline compliance checking but also
be deployed (together with workflow, user interface and
other components) in clinical decision support systems
assisting practitioners and patients at the point of care.
In order to further validate our methodology, the aim
of this project was to test it on thousands of real stroke
patient case files from the SITS registry and compare
the results to those obtained from conventional data
analysis using standard statistical software, which we re-
cently reported for a clinical audience [11].
Methods
We have described the openEHR-based methodology
previously, when tested in an experimental setting [10].
The following summarises the main elements of this
methodology:
– Archetypes: reusable models of clinical concepts,
which undergo review in order to standardise them.
An archetype could, for example, represent a blood
pressure observation or diagnosis decision.
Archetypes can be reviewed on regional, national
and international levels. They are supposed to
represent maximal data sets, i.e. if an archetype
represents a diagnosis decision, then any organisation
needing to deal with diagnosis-related data should be
able to retrieve the data it needs from a high quality
diagnosis archetype. Also, archetype data elements can
be bound to standardised terms from terminologies like
SNOMED CT or ICD.
– GDL rules: rules defined in GDL base their data
acquisition on archetype data elements as well as
provide their output (an alert, for instance) as
archetype data elements. GDL, too, supports binding
data to terminologies. Data in GDL rules can be
associated with multiple terminologies simultaneously.
Figure 1 shows an example of a GDL rule.
It is worth noting that our methodology does not sup-
port workflow aspects, adaptive behaviour or the specifica-
tion of clinical intentions and exceptions. Within a clinical
decision support system, these components and other
process modelling technologies would complement GDL
technology in its current form.
The tools we used to apply our methodology are:
– The international archetype repository,1 i.e. the
international instance of the ‘Clinical Knowledge
Manager’, to retrieve existing archetypes.
– The free and open-sourced Archetype Editor2 to
author new archetypes or modify existing ones.
– The free and open-sourced GDL Editor3 to author
GDL rules.
– The CDS Workbench by Cambio Healthcare
Systems to run GDL rules on archetyped data.
The details of the produced archetypes and GDL rules,
which have not changed for this use case, can be found
in our previous publication [10]. For mapping data from
the SITS registry into a format that the CDS Workbench
can work with and running the compliance checks, we
went through the following steps:
1. SITS registry data, in form of a comma-separated
values (CSV) file, were split into multiple CSV files
which aligned with archetype structures. For each
archetype, e.g. a blood glucose archetype, we created
a separate CSV file that contained the data related
to that particular medical aspect of European stroke
treatment recommendations (blood glucose thresh-
olds, in this case), in addition to patient treatment
file numbers (see Additional files 1, 2, 3, 4, 5 and 6
for examples of the produced files).
In our use case of acute stroke treatment, the
mapping was rather straightforward. Data elements
from the original CSV files were either available in
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existing archetypes or we created archetypes for
them where we could not find those data elements
in common repositories (without creating
redundancy or overlap in archetype concepts
between new and existing archetypes). We did not
encounter the problem of using an archetype with
mandatory data values that were not available in the
registry. In the opposite case, it was possible to
modify an archetype by extending its data
definitions.
We decided whether a registry data item was
equivalent to an archetype data element by
 discussing the meaning of the registry data item
with SITS clinical specialists if the data item’s
label left any reason for doubt,
 checking the description of the archetype data
element through the description part that
accompanies every archetype data element and
checking the general archetype meta-data (in
addition to archetype review information, if
necessary) and then
 judging the equivalence.
2. We ran GDL rules on the CSV files using the CDS
Workbench. The CDS Workbench essentially
connects the relevant GDL rules with archetyped
patient data. The CDS Workbench operates directly
on the newly created CSV files, creating in-memory
representations of the relevant archetype objects and
GDL rules. Note also that the GDL rules as such are
specified in terms of archetype data elements, e.g. in
the rule
["gt0004"] = (RULE) <
when = <"$gt0020==null",
"($gt0018<50,mg/
dl)||($gt0018>400,mg/dl)">
then = <"$gt0049=true", "$gt0020=true">
the code gt0018 represents an archetype element for
blood glucose as a quantity and is directly derived
from a corresponding archetype in a previous section
of the GDL code:
["gt0017"] = (ARCHETYPE_BINDING) <
archetype_id = <"openEHR-EHR-
OBSERVATION.lab_test-
blood_glucose.v1">
domain = <"EHR">
elements = <
["gt0018"] = (ELEMENT_BINDING) <
path =
<"/data[at0001]/events[at0002]/
data[at0003]
/items[at0078.2]"
3. The CDS Workbench produced proportions of
patients treated in non-compliance with guidelines.
4. We created additional GDL rules to account for
missing values, which the CDS Workbench then
counted so that we could exclude them from the
compliance calculations. This was necessary since
the standardised archetype objects were in-memory,
without the ability to affect them directly in the
Fig. 1 A GDL Rule. A GDL rule as presented within the free and open-sourced tool GDL Editor. Here exceeding a blood pressure threshold
contraindicates thrombolysis treatment. The blue parts constitute data elements coming from reusable clinical content models in the form
of archetypes
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compliance checking configuration (see also point
2 above).
We applied this method to check the compliance of
patient cases (18,400 patients) from across Europe (19
countries, 232 hospitals) with European Stroke Organisa-
tion guidelines and European Medicines Agency regula-
tions for using intravenous thrombolysis in the treatment
of acute ischaemic stroke. We have reported the criteria
that led to our patient samples and their clinical import-
ance, which was to provide a basis for studying the way
compliance with recommendations changed following a
guideline update. The update had been introduced in two
documents published in 2008 and 2009, so we studied two
samples of patients from hospitals enrolling cases in SITS
both in the years 2006 to 2007 (n = 6354) as well as 2010
to 2011 (n = 12,046) [11].
Finally, we compared the compliance rates from our
method presented here with the results we obtained in
the clinical study above [11], which had used conven-
tional statistical analysis.
Results
Our method yielded the same rates of non-compliance
as using conventional statistical software. This shows that
GDL-based technology is reliable when applied to thou-
sands of real patient data files (from 18,400 patients in this
case) and thus applicable to large and complex clinical
registries. Table 1 and Fig. 2 show examples of our results.
This also shows that our methodology can be used to
assist in monitoring of quality of care and in clinical re-
search. In this case, the GDL technology showed that clini-
cians promptly adhered to the European guideline update
from 2009 that increased the time window for stroke treat-
ment from 3 to 4.5 h after symptom onset, reflected by
higher non-compliance with the contraindication ‘Stroke
onset > 3 h ago’ in 2010 and 2011. Similarly, the guideline
update allowed the treatment of patients aged over 80 years,
also reflected by higher non-compliance with the contra-
indication ‘Age > 80 years’ (Table 1).
The results obtained here were a complete match for
each single patient, regarding all compliance criteria. Since
there were no exceptions to this, presenting our results on
a case-by-case (patient-by-patient) basis would not con-
tribute additional insight, as all compliance criteria we
checked (see Table 1) evaluated to either true or false.
Discussion
We have demonstrated for the first time that it is possible
to retrospectively check the compliance of thousands of
real patient cases with guideline recommendations using a
technology that is based on openEHR’s Guideline Defin-
ition Language and a patient data registry. We utilised the
SITS registry for obtaining patient data. By doing so, we
validated the results of a previous experiment that was
limited to a small number of mock patient cases [10], and
took an important step toward further implementation of
such methods in electronic health record systems and pa-
tient registries.
Limitations
One limitation of this study is related to tools supporting
the use of GDL. The CDS Workbench did not have
built-in functions to deal with missing data values, so we
had to create extra GDL rules in the GDL Editor. Fur-
thermore, we had to map the SITS registry database to
an openEHR-specific CSV database, which constituted
an additional work step.
The fact that GDL artefacts provided both guideline
recommendations and a means of configuring the com-
pliance checking implementation (e.g. to deal with miss-
ing values) presents a problem of different purposes
being mixed together, and may thus make GDL rules
less maintainable and less reusable in the long term.
Another limitation is that this technology is not suited
to measure the statistical significance of the obtained re-
sults. Such calculations would typically have to be done
by a separate application.
Mapping vs. interoperability
Our methodology could not be applied directly to the
CSV file that was exported from the SITS registry and
thus this work included a manual mapping step (see the
Table 1 Results of non-compliance obtained by openEHR’s
Guideline Definition Language (GDL) and compared to
conventional analysis
Contraindication to Thrombolysis
Treatment
Non-Compliance (%)
2006–2007 2010–2011
CA GDL CA GDL
NIHSS score > 25 1.1 1.1 1.7 1.7
Anticoagulation treatment 2.4 2.4 3.1 3.1
Systolic blood pressure > 185 mmHg 2.5 2.5 5.4 5.4
Systolic blood pressure > 184 mmHg 4.0 4.0 6.3 6.3
Diastolic blood pressure > 110 mmHg 0.8 0.8 2.1 2.1
Diastolic blood pressure > 109 mmHg 2.1 2.1 3.6 3.6
Diabetes and previous stroke 2.5 2.5 2.8 2.8
Blood glucose < 50 mg/dl or > 400 mg/dl 0.3 0.3 0.3 0.3
Age > 80 years 8.9 8.9 17.2 17.2
Stroke onset > 3 h ago 8.2 8.2 27.9 27.9
Stroke onset > 4.5 h ago 0.9 0.9 1.8 1.8
The guidelines and regulations from the European Stroke Organisation [23, 24]
and European Medicines Agency [25] respectively are in the form of
contraindications to the use of a decisive stroke treatment – intravenous
thrombolysis. These results from GDL and archetypes completely match results
from conventional statistical software where the clinical question was studied
in detail [11]
CA conventional analysis, NIHSS National Institutes of Health Stroke Scale
Anani et al. BMC Medical Informatics and Decision Making  (2017) 17:7 Page 4 of 8
section Limitations above), which can be seen to hamper
interoperability. The target of the mapping still followed
the structure of standardised archetypes, producing
shareable mapped artefacts if another system wants to
implement the same kind of openEHR-specific CSV
database. Optimally, an openEHR-based system would
provide the underlying structure of the registry in
question.
Also, when dealing with legacy systems, some form of
manual mapping will always be required if the original
model is not used to represent clinical guidelines.
The nature of clinical practice guidelines and how GDL
fits in
In our experience, clinical practice guidelines from dif-
ferent clinical domains (i.e. not only from acute stroke
management) tend to contain their recommendations in
a condensed form that is transferrable to computational
formats of the if-then-else type. Furthermore, it is be-
coming increasingly common to release guidelines with
accompanying flowcharts (e.g. guidelines released by
NICE [12] and NGC [13]) that are equally computable
with rule-conformant structures as they take place in the
GDL implementation presented herein.
However, it is important to keep in mind that there
are still certain clinical scenarios (e.g. complex chemo-
therapy regimens) that require more complex structures
than GDL functionality can accommodate at this point.
A complete clinical situation with all its socio-technical
complexities also requires additions to pure rule-based
logic such as workflow support and situation awareness.
Having said that, it is also important to be aware of
the characteristics of a guideline’s recommendations when
attempting to computerise those using GDL. While GDL’s
functionality has been undergoing continuous improve-
ments since the release of the language in 2013, it is help-
ful to keep in mind that the typical use cases today are
those that can be represented using common mathemat-
ical functions that entail comparison of data values to each
other or thresholds using mathematical operators, or in-
volve setting values using standardised terminology codes
or mathematical formulae.
Arguably one of the biggest strengths of GDL lies in
its ability to solve the ‘curly braces problem’, i.e. the inef-
ficient reliance on locally defined data models for re-
trieving data needed by guideline logic. GDL solves that
by being based on archetypes, standard data models and
standard terminologies. Furthermore, technical concerns
such as runtime rules’ language syntax and mappings to
local clinical models are not mixed with the clinical
views of the rules which are meant to be used and veri-
fied by clinicians.
Implications for patient care
Being able to check guideline or protocol compliance on
retrospective patient data can give managers or other
stakeholders in health care an opportunity to see the
performance of their respective organisations when it
comes to following the latest evidence and state of the
art in their fields. Also, it allows conducting clinical re-
search that may investigate reasons for certain compli-
ance patterns.
Fig. 2 Results Display. The tool CDS Workbench produced non-compliance rates as pie charts using GDL. Each pie chart relates to one of the
contraindications to thrombolysis treatment in acute ischaemic stroke as laid out in European guidelines and regulations
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Interoperability, shareability and reusability
When the above benefits are based on interoperability
specifications this adds the advantages that
– data from several organisations, which follow a
certain interoperability standard, can be investigated
at the same time and
– all organisations implementing a certain
interoperability standard can share and maintain the
same guideline knowledge models.
The execution of standardised models of clinical and
guideline knowledge, like openEHR archetypes and GDL
rules, does not have to be limited to retrospective check-
ing of guideline compliance, but could enhance clinical
decision making at the point of care. The same GDL
rules used for compliance checking could, for instance,
lead to notifying a clinician about a deviation from a
guideline recommendation in a prescription order they
have just placed.
openEHR-based clinical decision support
While this work focussed on retrospective functionality,
there have long been aspirations and experiences when
it comes to using openEHR technologies for providing
point-of-care decision support.
González-Ferrer et al. report positive results about the
adequacy of openEHR archetypes within the specifica-
tion of decision support-specific clinical statements [14].
Chen et al. demonstrate initial successes in deploying a
regional clinical decision support system based on GDL
[15]. In a further effort, Xiao et al. use archetypes to de-
velop decision support functionality in the clinical area
of methadone-based therapy [16].
Meanwhile, when looking at a higher level picture of
how different semantic components come together to
achieve clinical decision support, the work herein fits
into three of the layers recently published by the European
SemanticHealthNet project: the openEHR archetypes fit
into the layer of structured heterogeneous data (layer 1),
and the GDL rules fit into the layers of semantic mediators
(layer 3) and virtual homogeneous data (layer 4). Reaching
a full clinical decision support system with sound seman-
tics will entail addressing the remaining two layers, but
some of that work falls outside the scope of interoperability
specifications as such, e.g. when application developers
realise the layer of applications based on their particular
business use cases [17].
Implications for the development and maintainability of
health records
In the long run, reusability, shareability and interoper-
ability advantages are likely to materialise into economic
advantages when developing and maintaining electronic
health records as well. Having reusable clinical content
models in the form of archetypes and reusable guideline
knowledge models in the form of GDL rules will further
foster effective software development and maintainabil-
ity. At the same time, the separation of clinical models
from technical models (two-level modelling), which is
one of the core openEHR solution constituents, will fur-
ther foster effective software engineering by harnessing
the benefits of model-driven development. Studies into
this have varied in their findings, where some had positive
insights about the effects of model-driven development in
openEHR-based solutions [18] and others discovered
challenges that still need to be solved in real world
implementations [19].
Directions for future work
Evaluating GDL technology at the point of care is an
important next step, as it could also lead to a better un-
derstanding about features which may be missing from
GDL’s functionality.
Also, introducing measures and procedures to achieve
quality assurance of GDL rules that may interest a wider
community could prove useful. One example of doing
this would be reviewing GDL rules the way archetypes
are reviewed today, which could lead to the advantage of
clear categorisation of GDL rules into the clinical do-
mains they belong to. Additionally, modifying GDL to
address a better separation of concerns where GDL rules
strictly deal with clinical guideline content and nothing
else would also lead to GDL rules of higher shareability
and maintainability value.
Furthermore, more comparisons are needed with simi-
lar research that has used other interoperability stan-
dards than openEHR or other computer-interpretable
guideline formalisms than GDL such as PROforma [20],
Asbru [21] or SAGE [22]. Eventually, it would be desirable
for more and more agreement to take place regarding a
minimum set of necessary functions for computerising
clinical practice guidelines for different purposes, which,
in turn, could lead to more standardisation and potentially
better patient care.
Conclusions
Registry-based analyses of compliance with clinical prac-
tice guidelines are possible with state-of-the-art technolo-
gies for interoperability. openEHR archetypes and GDL
rules could be applied to detect deviations from best
practice, guidelines or regulations. Furthermore, such
technologies may be worth considering when taking
measures to improve continuity of care, quality of care,
clinical research and clinical decision making.
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Endnotes
1http://www.openehr.org/ckm
2http://www.openehr.org/downloads/archetypeeditor/
home
3http://sourceforge.net/projects/gdl-editor/
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